AU1440601A - Cytotoxic t lymphocyte-stimulating peptides for prevention, treatment, and diagnosis of melanoma - Google Patents

Cytotoxic t lymphocyte-stimulating peptides for prevention, treatment, and diagnosis of melanoma

Info

Publication number
AU1440601A
AU1440601A AU14406/01A AU1440601A AU1440601A AU 1440601 A AU1440601 A AU 1440601A AU 14406/01 A AU14406/01 A AU 14406/01A AU 1440601 A AU1440601 A AU 1440601A AU 1440601 A AU1440601 A AU 1440601A
Authority
AU
Australia
Prior art keywords
lymphocyte
melanoma
cytotoxic
diagnosis
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU14406/01A
Inventor
Kevin T. Hogan
Mark H. Ross
Craig L Slingluff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Argonex Pharmaceuticals Inc
Original Assignee
ARGONEX PHARMACEUTICALS Inc
Argonex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ARGONEX PHARMACEUTICALS Inc, Argonex Pharmaceuticals Inc filed Critical ARGONEX PHARMACEUTICALS Inc
Publication of AU1440601A publication Critical patent/AU1440601A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A61K39/464492—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU14406/01A 1999-10-29 2000-10-27 Cytotoxic t lymphocyte-stimulating peptides for prevention, treatment, and diagnosis of melanoma Abandoned AU1440601A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16248099P 1999-10-29 1999-10-29
US60162480 1999-10-29
PCT/US2000/029679 WO2001032193A1 (en) 1999-10-29 2000-10-27 Cytotoxic t lymphocyte-stimulating peptides for prevention, treatment, and diagnosis of melanoma

Publications (1)

Publication Number Publication Date
AU1440601A true AU1440601A (en) 2001-05-14

Family

ID=22585794

Family Applications (1)

Application Number Title Priority Date Filing Date
AU14406/01A Abandoned AU1440601A (en) 1999-10-29 2000-10-27 Cytotoxic t lymphocyte-stimulating peptides for prevention, treatment, and diagnosis of melanoma

Country Status (2)

Country Link
AU (1) AU1440601A (en)
WO (1) WO2001032193A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7413894B2 (en) * 2003-07-01 2008-08-19 University Of Virginia Patent Foundation TAG-1 and TAG-2 proteins and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034613A1 (en) * 1996-03-19 1997-09-25 University Of Virginia Patent Foundation Peptides recognized by melanoma-specific a1-, a2- and a3-restricted cytotoxic lymphocytes, and uses therefor
JP2002507397A (en) * 1998-03-13 2002-03-12 エピミューン，インコーポレイティド HLA binding peptides and uses thereof

Also Published As

Publication number Publication date
WO2001032193A1 (en) 2001-05-10

Similar Documents

Publication Publication Date Title
AU4205100A (en) Methods and compositions for the treatment of pancreatitis
AU6489600A (en) Patient monitor
MXPA01012184A (en) Dietary or pharmaceutical composition for use for the prevention or treatment of hyperoxaluria.
AU4498400A (en) Nb-ti-zr-mo alloys for medical and dental devices
AU2197100A (en) Treatment of tooth surfaces and substance therefor
AU3791601A (en) Treatment of coal
AU2977700A (en) Personal physiological monitor
AU2002248319A1 (en) Pharmaceutical composition for the prevention and treatment of scar tissue
AU2508597A (en) Drug for the treatment of tumours
AU2208401A (en) Inhibitors of complement activation, their preparation and use
AU2002226030A1 (en) Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
AU1067599A (en) Peptide compositions for the treatment and prevention of hiv infection
AU5215300A (en) Dental treatment area
EP1144639A3 (en) Compounds and methods for the diagnosis and treatment of ehrlichia infection
AU6425800A (en) Agents for the diagnosis, prognosis and treatment of malignant diseases
AU3896900A (en) Treatment of pain
AU1878201A (en) Composition for the treatment of damaged tissue
AU4654500A (en) Prevention, diagnosis and treatment of lyme disease
AU2002330724A1 (en) Diagnosis, prevention and treatment of cancer
AU4259299A (en) New sequences of tt viruses for use in diagnosis, prevention and treatment of ttv infections
AU2001291994A1 (en) Dipeptide ligands of the npff receptor for treating pain and hyperalgesia
AU1440601A (en) Cytotoxic t lymphocyte-stimulating peptides for prevention, treatment, and diagnosis of melanoma
EP1250145A4 (en) C-ski oncogene-derived peptides for prevention, treatment, and diagnosis of cancer
AU2566201A (en) Compounds and methods for the treatment of pain
AU2593597A (en) Compositions for the diagnosis and treatment of chediak-higashi syndrome

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase